Search research articles
Contact Us
Filters
Showing results (591-600 of 610) with videos related to
Page
of 61
Sort By:
Blood
|
November 25, 2010
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
Hagop M Kantarjian, Francis J Giles, Kapil N Bhalla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 22, 2018
Anaplastic Lymphoma Kinase Mutation (<i>ALK</i> F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib
Benedito A Carneiro, Sahithi Pamarthy, Ami N Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2005
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies
Karen W L Yee, Anne Hagey, Srdan Verstovsek, et al.
Neurosurgery
|
September 7, 2018
Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
John Lynes, Sadhana Jackson, Victoria Sanchez, et al.
Leukemia
|
June 4, 2010
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
F J Giles, E Abruzzese, G Rosti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2002
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results
Hagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2020
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
Sandip P Patel, Megan Othus, Young Kwang Chae, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 20, 2023
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies
Benedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, et al.
Nature Medicine
|
April 14, 2026
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial
Devalingam Mahalingam, Rachna T Shroff, Benedito A Carneiro, et al.
Leukemia
|
October 7, 2015
Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
A Hochhaus, G Rosti, N C P Cross, et al.
Page
of 61
Search research articles
Search
Showing results (591-600 of 610) with videos related to
Sort By:
Page
of 61
Blood
|
November 25, 2010
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
Hagop M Kantarjian, Francis J Giles, Kapil N Bhalla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 22, 2018
Anaplastic Lymphoma Kinase Mutation (<i>ALK</i> F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib
Benedito A Carneiro, Sahithi Pamarthy, Ami N Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2005
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies
Karen W L Yee, Anne Hagey, Srdan Verstovsek, et al.
Neurosurgery
|
September 7, 2018
Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
John Lynes, Sadhana Jackson, Victoria Sanchez, et al.
Leukemia
|
June 4, 2010
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
F J Giles, E Abruzzese, G Rosti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2002
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results
Hagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2020
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
Sandip P Patel, Megan Othus, Young Kwang Chae, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 20, 2023
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies
Benedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, et al.
Nature Medicine
|
April 14, 2026
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial
Devalingam Mahalingam, Rachna T Shroff, Benedito A Carneiro, et al.
Leukemia
|
October 7, 2015
Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
A Hochhaus, G Rosti, N C P Cross, et al.
Page
of 61